Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139392 | 1.00 | SLC6A5 (0.55) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL26032972 | 1.00 | SLC6A5 (0.55) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL26032397 | 1.00 | SLC6A5 (0.55) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL25735688 | 1.00 | SLC6A5 (0.55) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL1987159 | 1.00 | SLC6A5 (0.55) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL1988266 | 0.98 | SLC6A5 (0.56) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL16524092 | 0.98 | SLC6A5 (0.56) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL20856400 | 0.98 | SLC6A5 (0.56) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL17817133 | 0.98 | SLC6A5 (0.56) | SLC6A5FAAHDNM1LPAR1LPAR2 | |
| SCHEMBL25067294 | 0.97 | SLC6A5 (0.52) | SLC6A5FAAHDNM1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2018-11-01 | — | — | US | claimed |
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2017-06-29 | — | — | US | claimed |
| US-9493583-B2 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ADOCIA (FR) | 2016-11-15 | — | — | US | claimed |
| EP-2741765-B9 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-09-28 | — | — | EP | claimed |
| EP-3053590-A1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | Adocia (FR) | 2016-08-10 | — | — | EP | claimed |
| EP-2741765-B1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-03-30 | — | — | EP | claimed |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2015-09-10 | — | — | US | claimed |
| US-9089476-B2 | Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2015-07-28 | — | — | US | claimed |
| EP-2741765-A1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | Adocia (FR) | 2014-06-18 | — | — | EP | claimed |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2013-03-14 | — | — | US | claimed |
| WO-2013021143-A1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2013-02-14 | — | — | WO | claimed |
| EP-2516473-B1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED WITH A DERIVATIVE OF HYDROPHOBIC ACID | ADOCIA (FR) | 2020-09-30 | — | — | EP | disclosed |
| US-10449256-B2 | Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer | ADOCIA (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2018-11-01 | — | — | US | disclosed |
| US-20180169249-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER | ADOCIA (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2013-03-14 | — | — | US | disclosed |
| WO-2013021143-A1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2013-02-14 | — | — | WO | disclosed |
| EP-2516473-A1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED BY A HYDROPHOBIC ACID DERIVATIVE | Adocia (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20110172166-A1 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ADOCIA (FR) | 2011-07-14 | — | — | US | disclosed |
| WO-2011077405-A1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED BY A HYDROPHOBIC ACID DERIVATIVE | ADOCIA (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | SLC6A5 481/4885FAAH 4107/4885DNM1 938/4885 |
| US-20110172166-A1 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ALG1, CD44, FUT6 | SLC6A5 1565/4885FAAH 3193/4885DNM1 4329/4885 |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | SLC6A5 481/4885FAAH 4107/4885DNM1 938/4885 |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | SLC6A5 481/4885FAAH 4107/4885DNM1 938/4885 |
| US-20180169249-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER | IAPP, IGFBP5, IDE | SLC6A5 1388/4885FAAH 3264/4885DNM1 3060/4885 |
| US-10449256-B2 | Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer | IAPP, IGFBP5, IDE | SLC6A5 1388/4885FAAH 3264/4885DNM1 3060/4885 |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | IAPP, IGFBP5, INSR | SLC6A5 481/4885FAAH 4107/4885DNM1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.